Subtype and Pathway Specific Responses to Anticancer Compounds in Breast Cancer
Subtype and pathway specific responses to anticancer SPECIAL FEATURE compounds in breast cancer Laura M. Heisera,1, Anguraj Sadanandama,1,2, Wen-Lin Kuoa, Stephen C. Benzb, Theodore C. Goldsteinb, Sam Ngb, William J. Gibba, Nicholas J. Wanga,Safiyyah Ziyada, Frances Tongc, Nora Bayania, Zhi Hua, Jessica I. Billiga, Andrea Duereggera, Sophia Lewisa, Lakshmi Jakkulaa, James E. Korkolaa, Steffen Durincka, François Pepina, Yinghui Guana, Elizabeth Purdomc, Pierre Neuvialc,3, Henrik Bengtssonc,4, Kenneth W. Woodd, Peter G. Smithe, FEATURE Lyubomir T. Vassilevf, Bryan T. Hennessyg, Joel Greshockh, Kurtis E. Bachmanh, Mary Ann Hardwickeh, John W. Parki, Laurence J. Martonj, Denise M. Wolfa, Eric A. Collissoni, Richard M. Nevea, Gordon B. Millsg, Terence P. Speedc,k, BREAST CANCER SPECIAL Heidi S. Feilera, Richard F. Woosterh, David Hausslerb,l, Joshua M. Stuartb, Joe W. Graya,5,6, and Paul T. Spellmana,6,7 aLife Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720; bDepartment of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California, Santa Cruz, CA 94720; cDepartment of Statistics, University of California, Berkeley, CA 94720; dCytokinetics, Inc., South San Francisco, CA 94080; eOncology, Millenium Pharmaceuticals, Cambridge, MA 02139; fHoffman-La Roche, Nutley, NJ 07110; gDepartment of Sytems Biology, MD Anderson Cancer Center, Houston, TX 77054; hGlaxoSmithKline, Collegeville, PA 19426; iDivision of Hematology-Oncology, University of California, San Francisco, CA 94143;
[Show full text]